Recent AMRA research examines whether the use of MRI-based biomarkers as surrogate endpoints in DMD clinical trials is feasible, allowing for more informative descriptions of disease severity and progression in DMD
Medical Research
AMRA at MDA 2025 – Presents research from one of the largest natural history studies to date, validating our unique, MRI-based biomarkers for use as endpoints in upcoming FSHD trials
LINKÖPING, Sweden, March 14, 2025 – AMRA Medical is muscling up for the 2025 Muscular Dystrophy Association’s Clinical and Scientific Conference (MDA…
AMRA presents new findings on chronic kidney disease and muscle composition at ICFSR 2025
LINKÖPING, Sweden, March 12, 2025 –We’re pleased to share that AMRA Medical—led by Markus Karlsson, PhD, and colleagues from Linköping and Lund Universities—will…
Pilot Study Demonstrates that AMRA’s Longitudinal Muscle Assessment Methodology is Feasible in Liver Transplant (LT) Candidates
LINKÖPING, Sweden, February 19, 2025 – A recent collaborative pilot project – led by Lisa VanWagner, MD, MSc of the University of Texas…
New study to be presented at the EASL-SLD summit shows that muscle composition predicts adverse outcomes in 5-year follow-up of patients with chronic liver disease, but not baseline fibrosis stage.
LINKÖPING, Sweden, January 22, 2025 –The 2025 EASL-SLD Summit – which runs from January 23-25th in beautiful Estoril, Portugal – brings together healthcare…
AMRA’s MRI assessments provide a unique understanding of weight loss in obesity
AMRA’s MRI-based biomarkers, including proprietary z-scores, offer a groundbreaking solution, providing researchers with a unique understanding of the nature and impact of these changes. By precisely measuring muscle volume and fat infiltration (an indicator of muscle quality), AMRA’s technology uncovers the hidden dynamics of weight loss, empowering the development of more effective therapies.